Cell therapy has reached significant milestones in various life-threatening diseases,
including cancer. Cell therapy using fluorescent and radiolabeled chimeric antigen receptor …

Opinion statement The therapeutic armamentarium has significantly expanded since the
approval of various CD19-targeting chimeric antigen receptor T cell (CAR-T) therapies in …

Splenic marginal zone B-cell lymphoma (SMZL) is a heterogeneous clinico-biological entity.
The clinical course is variable, multiple genes are mutated with no unifying mechanism, and …

Our objective was to compare the diagnostic performance of 68Ga-labeled fibroblast
activation protein (FAP) inhibitor (FAPI) and 18F-labeled FDG PET/CT in diagnosing …

The tumor microenvironment (TME)–a term comprising non‐neoplastic cells and
extracellular matrix as well as various cytokines, chemokines, growth factors, and other …

Recent breakthroughs in research have sparked a paradigm shift in our understanding of
cancer biology, uncovering the critical role of the crosstalk between tumor cells and the …

Chimeric antigen receptor T cell (CAR T) therapy is a potent treatment for relapsed/refractory
(r/r) B cell lymphomas but provides lasting remissions in only∼ 40% of patients and is …

Abstract Non-Hodgkin lymphomas (NHLs) are heterogeneous and are among the most
common hematological malignancies worldwide. Despite the advances in the treatment of …

Diffuse large B cell lymphoma (DLBCL) exhibits a tightly complexity immune landscape. In
this study, we intended to identify different immune phenotype and to examine the immune …

Background PTTG1 has been reported to be linked with the prognosis and progression of
various cancers, including kidney renal clear cell carcinoma (KIRC). In this article, we mainly …